Here are four takeaways:
1. The ongoing Phase 2 clinical trial data shows CK-2127107 improved muscle function in mouse models with spinal muscular atrophy.
2. Researchers found single doses of CK-2127107 boosted isometric force in situ in response to sub-tetanic nerve stimulation in the mouse models.
3. CK-2127107 decreased the rate of “calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium, leading to an increase in skeletal muscle contractility.”
4. Cytokinetics is working with Northbrook, Ill.-based Astellas Pharma to offer CK-2127107 as a treatment for people with SMA as well as other conditions associated with skeletal muscle weakness.
More articles on spine:
8 things for spine surgeons to know for Thursday — March 23, 2017
Medtronic, DePuy Synthes & Stryker lead North American bone grafts & substitutes market — 7 observations
Long Beach Memorial opens Spine Center doors: 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.